These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

143 related items for PubMed ID: 15102016

  • 1. Synthetic selective inhibitors of coagulation factor Xa strongly inhibit thrombin generation without affecting initial thrombin forming time necessary for platelet activation in hemostasis.
    Ieko M, Tarumi T, Takeda M, Naito S, Nakabayashi T, Koike T.
    J Thromb Haemost; 2004 Apr; 2(4):612-8. PubMed ID: 15102016
    [Abstract] [Full Text] [Related]

  • 2. Antithrombotic and hemorrhagic effects of DX-9065a, a direct and selective factor Xa inhibitor: comparison with a direct thrombin inhibitor and antithrombin III-dependent anticoagulants.
    Morishima Y, Tanabe K, Terada Y, Hara T, Kunitada S.
    Thromb Haemost; 1997 Nov; 78(5):1366-71. PubMed ID: 9408021
    [Abstract] [Full Text] [Related]

  • 3. Inactivation of factor Xa by the synthetic inhibitor DX-9065a causes strong anticoagulant and antiplatelet actions in human blood.
    Kaiser B, Jeske W, Walenga JM, Fareed J.
    Blood Coagul Fibrinolysis; 1999 Dec; 10(8):495-501. PubMed ID: 10636461
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Species differences in anticoagulant and anti-Xa activity of DX-9065a, a highly selective factor Xa inhibitor.
    Hara T, Yokoyama A, Morishima Y, Kunitada S.
    Thromb Res; 1995 Oct 01; 80(1):99-104. PubMed ID: 8578544
    [Abstract] [Full Text] [Related]

  • 6. Global anticoagulant effects of a synthetic anti-factor Xa inhibitor (DX-9065a): implications for interventional use.
    Tobu M, Iqbal O, Ma Q, Schultz C, Jeske W, Hoppensteadt D, Lewis B, Fareed D, Fareed J.
    Clin Appl Thromb Hemost; 2003 Jan 01; 9(1):1-17. PubMed ID: 12643318
    [Abstract] [Full Text] [Related]

  • 7. Effects of a factor Xa inhibitor, DX-9065a, in a novel rabbit model of venous thrombosis.
    Rogers KL, Chi L, Rapundalo ST, Kramer JB, Gallagher KP.
    Basic Res Cardiol; 1999 Feb 01; 94(1):15-22. PubMed ID: 10097826
    [Abstract] [Full Text] [Related]

  • 8. Studies on the different modes of action of the anticoagulant protease inhibitors DX-9065a and Argatroban. II. Effects on fibrinolysis.
    Nagashima H.
    J Biol Chem; 2002 Dec 27; 277(52):50445-9. PubMed ID: 12397070
    [Abstract] [Full Text] [Related]

  • 9. Inhibition of thrombin generation in plasma by inhibitors of factor Xa.
    Prasa D, Svendsen L, Stürzebecher J.
    Thromb Haemost; 1997 Oct 27; 78(4):1215-20. PubMed ID: 9364987
    [Abstract] [Full Text] [Related]

  • 10. Differential effects of DX-9065a, argatroban, and synthetic pentasaccharide on tissue thromboplastin inhibition test and dilute Russell's viper venom test.
    Gerbutavicius R, Iqbal O, Messmore HL, Wehrmacher WH, Hoppensteadt DA, Gerbutaviciene R, Griniute R, Fareed J.
    Clin Appl Thromb Hemost; 2003 Oct 27; 9(4):317-23. PubMed ID: 14653441
    [Abstract] [Full Text] [Related]

  • 11. The effects of argatroban on thrombin generation and hemostatic activation in vitro.
    Tanaka KA, Szlam F, Katori N, Sato N, Vega JD, Levy JH.
    Anesth Analg; 2004 Nov 27; 99(5):1283-1289. PubMed ID: 15502018
    [Abstract] [Full Text] [Related]

  • 12. Apixaban, a direct factor Xa inhibitor, inhibits tissue-factor induced human platelet aggregation in vitro: comparison with direct inhibitors of factor VIIa, XIa and thrombin.
    Wong PC, Jiang X.
    Thromb Haemost; 2010 Aug 27; 104(2):302-10. PubMed ID: 20589316
    [Abstract] [Full Text] [Related]

  • 13. Inhibitors of blood coagulation factors Xa and IIa synergize to reduce thrombus weight and thrombin generation in vivo and in vitro.
    Gould WR, McClanahan TB, Welch KM, Baxi SM, Saiya-Cork K, Chi L, Johnson TR, Leadley RJ.
    J Thromb Haemost; 2006 Apr 27; 4(4):834-41. PubMed ID: 16634754
    [Abstract] [Full Text] [Related]

  • 14. DX 9065A a novel, synthetic, selective and orally active inhibitor of factor Xa: in vitro and in vivo studies.
    Herbert JM, Bernat A, Dol F, Hérault JP, Crépon B, Lormeau JC.
    J Pharmacol Exp Ther; 1996 Mar 27; 276(3):1030-8. PubMed ID: 8786532
    [Abstract] [Full Text] [Related]

  • 15. Monitoring effects of direct FXa-inhibitors with a new one-step prothrombinase-induced clotting time (PiCT) assay: comparative in vitro investigation with heparin, enoxaparin, fondaparinux and DX 9065a.
    Graff J, Picard-Willems B, Harder S.
    Int J Clin Pharmacol Ther; 2007 Apr 27; 45(4):237-43. PubMed ID: 17474542
    [Abstract] [Full Text] [Related]

  • 16. In vivo evaluation of DX-9065a, a synthetic factor Xa inhibitor, in experimental vein graft.
    Kim DI, Kambayashi J, Shibuya T, Sakon M, Kawasaki T.
    J Atheroscler Thromb; 1996 Apr 27; 2(2):110-6. PubMed ID: 9225218
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. A synthetic selective inhibitor of factor Xa, DX-9065a, reduces monocyte chemoattractant protein-1 expression after ischemia-reperfusion injury in rat liver.
    Yamaguchi Y, Okabe K, Liang J, Matsumura F, Ohshiro H, Ishihara K, Matsuda T, Takeya M, Kuratsu JI, Mori K, Yamada S, Ogawa M.
    Dig Dis Sci; 1999 Dec 27; 44(12):2568-76. PubMed ID: 10630515
    [Abstract] [Full Text] [Related]

  • 20. Antithrombotic effects of a synthetic inhibitor of activated factor X, JTV-803, in animals.
    Hayashi M, Matsuo A, Nakamoto H, Aisaka K.
    Eur J Pharmacol; 2001 Jan 19; 412(1):61-6. PubMed ID: 11166737
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.